These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 20832665

  • 1. Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with d(90) ≥180 Gy.
    Gómez-Iturriaga Piña A, Crook J, Borg J, Ma C.
    Int J Radiat Oncol Biol Phys; 2010 Oct 01; 78(2):422-7. PubMed ID: 20832665
    [Abstract] [Full Text] [Related]

  • 2. High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data.
    Ghilezan M, Martinez A, Gustason G, Krauss D, Antonucci JV, Chen P, Fontanesi J, Wallace M, Ye H, Casey A, Sebastian E, Kim L, Limbacher A.
    Int J Radiat Oncol Biol Phys; 2012 Jul 01; 83(3):927-32. PubMed ID: 22197086
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer.
    Demanes DJ, Martinez AA, Ghilezan M, Hill DR, Schour L, Brandt D, Gustafson G.
    Int J Radiat Oncol Biol Phys; 2011 Dec 01; 81(5):1286-92. PubMed ID: 21310546
    [Abstract] [Full Text] [Related]

  • 6. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.
    Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M.
    Int J Radiat Oncol Biol Phys; 2013 Feb 01; 85(2):370-7. PubMed ID: 22672747
    [Abstract] [Full Text] [Related]

  • 7. (125)I monotherapy using D90 implant doses of 180 Gy or greater.
    Kao J, Stone NN, Lavaf A, Dumane V, Cesaretti JA, Stock RG.
    Int J Radiat Oncol Biol Phys; 2008 Jan 01; 70(1):96-101. PubMed ID: 17980505
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Ito K, Saitoh J, Noda SE, Harashima K, Sakurai H, Nakayama Y, Yamamoto T, Suzuki K, Nakano T, Niibe H.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):463-71. PubMed ID: 16168838
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged<or=55 years with favorable prostate cancer.
    Gómez-Iturriaga Piña A, Crook J, Borg J, Lockwood G, Fleshner N.
    Urology; 2010 Jun 01; 75(6):1412-6. PubMed ID: 20035986
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer.
    Siddiqui ZA, Gustafson GS, Ye H, Martinez AA, Mitchell B, Sebastian E, Limbacher A, Krauss DJ.
    Int J Radiat Oncol Biol Phys; 2019 Aug 01; 104(5):1038-1044. PubMed ID: 30771408
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.